NSCEB Statement on Pentagon’s Updated List of Chinese Military Companies Operating in U.S.

WASHINGTON – Today, the Chair and Vice Chair of the National Security Commission on Emerging Biotechnology (NSCEB), Senator Todd Young (R-Ind.) and Dr. Michelle Rozo, released the following statement addressing the recently updated 1260H list of “Chinese military companies” operating directly or indirectly in the United States: “In April 2025, the NSCEB highlighted the vulnerability our current reliance on Chinese biotechnology firms creates for U.S. national security and called for a prohibition on the use of biotechnology suppliers that are deemed to pose a national security threat. We applaud the Pentagon for taking concrete steps this week to update its 1260H list with the addition of Chinese biotechnology companies that have known ties to the Chinese military. We must also reinforce the American biotech ecosystem, including through investing in alternatives to Chinese biotech companies of concern, so that our industry is built on a foundation of trusted suppliers and service providers.” The Pentagon’s Section 1260H list identifies Chinese companies operating in the United States that the Department of War determines have ties to China’s military or military-civil fusion strategy. Companies on the list face increased scrutiny and restrictions on certain U.S. government contracting and business activities. Read the NSCEB’s April 2025 Action Plan and roadmap for U.S. biotechnology here: www.biotech.senate.gov/final-report About NSCEB: The National Security Commission on Emerging Biotechnology is a time-limited, high-impact legislative branch advisory entity whose purpose is to advance and secure biotechnology, biomanufacturing, and associated technologies for U.S. national security and to prepare the United States for the bioindustrial revolution. The Commission published a comprehensive report in April 2025, including recommendations for action by Congress and the federal government. The bipartisan Commission is composed of Congressionally-appointed Commissioners with members from both the Senate and the House of Representatives, as well as experts from industry, academia, and government. For more information about the Commission and to view the report, visit: biotech.senate.gov .